Cumberland Pharmaceuticals announced it will provide an update on its ifetroban drug candidate, which is being developed to treat cardiomyopathy linked to Duchenne muscular dystrophy (DMD). The update will be shared during a webcast and conference call on October 26, 2026. This event allows investors and interested parties to learn about the progress of ifetroban, a therapy aimed at addressing a significant unmet medical need in DMD patients. The company is also exploring ifetroban for other serious conditions like systemic sclerosis and idiopathic pulmonary fibrosis.
Cumberland Pharmaceuticals' update on its ifetroban DMD program is presented here alongside Pluang's health sector market data as of Oct 20, 2026 03:02 WIB. Among 150 health-sector US stocks, 87 advanced and 62 declined. Notably, Tango Therapeutics Inc. (TNGX) rose 7.08% to USD 23.60 with a typical hold time of 5 days, contrasting with AbCellera Biologics Inc (ABCL) which fell 6.94% to USD 11.80 and saw 100% sell order activity with a longer hold time of 41 days. Summit Therapeutics Inc (SMMT) gained 6.63% to USD 15.60 with balanced buy/sell orders and a 17-day hold time.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
